Check out the week’s top stories.
Twenty-nine HRSA-funded health centers to receive a boost in technology to improve outcomes.
The American Urogynecologic Society (AUGS) published an executive summary on postoperative opioid prescribing after female pelvic medicine and reconstructive surgery.
Gone are the days of little guidance for weight gain during pregnancy, but determining the best weight range has been elusive. A new study provides some helpful advice.
Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Don’t dread a call from OCR investigators. They are here to help physicians and other providers avoid astronomical monetary penalties.